Literature DB >> 22657738

[Evaluation of the incidence of upper gastrointestinal bleeding in Spain in relation to the taking of anti-ulcer agents].

Carlos Alvarez-Ibáñez1, María Mercedes Guerra-García.   

Abstract

OBJECTIVE: To analyse trends in the incidence of hospitalisation due to upper gastrointestinal bleeding (UGB) and the relationship with the prescribing of anti-ulcer agents.
DESIGN: Retrospective observational ecological study.
SETTING: Spanish National Health System (NHS) for the nine years between 1st January 2000 and 31st December 2008. INCLUSION CRITERIA: Patients aged 15 or over hospitalised due to UGB were divided into four age groups: 15-44, 45-64, 65-74 and ≥75 years old. Drugs, A02B subgroup, prescribed under the NHS. EXCLUSION CRITERIA: Prescription of medicines in hospital or public-employee insurance companies. MEASUREMENTS: Incidence (number of new cases of UGB occurring in one year), Incidence rate (incidence per 100,000 inhabitants), Dispersion rate (number of packets dispensed per year per 100,000 inhabitants), and Hazard ratio (HR, ratio between the rate of the last year over the first year. Annual rates were calculated by the standardised direct method). DATA SOURCE: Ministry of Health.
RESULTS: We identified 110,150 hospital admissions due to UGB (61.17% male, 38.83% female). Values for 95% UGB: Total Mean Incidence Rate (MIR)=34.45 [32.70, 36.20], HR=0.83. Males: MIR=43.07 [40.41, 45.72], HR=0.80 and females: MIR=25.20 [25.18, 27.23], HR=0.88. HR HDA by age group in males: 15-44 years=0.64; 45-64 years=0.74, 65-74 years=0.74 and >74 years=0.85. Females: 15-44 years=0.82, 45-64 years=0.71, 65-74 years=0.3 and >74 years=0.89. Drug dispensing (2000-2008): HR proton pump inhibitors=4.43; HR all anti-ulcer agents=3.01.
CONCLUSIONS: Over nine years the dispensing of anti-ulcer agents by the Spanish National Health System has multiplied without having regard to the evolutionary trend of hospitalisation due to UGB.
Copyright © 2011 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22657738      PMCID: PMC7025277          DOI: 10.1016/j.aprim.2012.01.004

Source DB:  PubMed          Journal:  Aten Primaria        ISSN: 0212-6567            Impact factor:   1.137


  10 in total

1.  Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users.

Authors:  Mitchell H Katz
Journal:  Arch Intern Med       Date:  2010-05-10

2.  [Study of prescription-indication of proton pump inhibitors].

Authors:  C de Burgos Lunar; S Novo del Castillo; E Llorente Díaz; M A Salinero Fort
Journal:  Rev Clin Esp       Date:  2006-06       Impact factor: 1.556

3.  Inappropriate prescribing of proton pump inhibitors in primary care.

Authors:  Bisanth Thushila Batuwitage; Jeremy G C Kingham; Nia Emma Morgan; Ruth Louise Bartlett
Journal:  Postgrad Med J       Date:  2007-01       Impact factor: 2.401

4.  Overprescribing PPIs: An old problem.

Authors:  A Breck McKay; Daryl Wall
Journal:  BMJ       Date:  2008-01-19

5.  Overprescribing proton pump inhibitors.

Authors:  Ian Forgacs; Aathavan Loganayagam
Journal:  BMJ       Date:  2008-01-05

6.  Opportunities to decrease inappropriate uses of proton pump inhibitors: Comment on "Proton pump inhibitor use and the antifracture efficacy of alendronate".

Authors:  Mitchell H Katz
Journal:  Arch Intern Med       Date:  2011-02-14

7.  Acid-suppressive medication use and the risk for nosocomial gastrointestinal tract bleeding.

Authors:  Shoshana J Herzig; Byron P Vaughn; Michael D Howell; Long H Ngo; Edward R Marcantonio
Journal:  Arch Intern Med       Date:  2011-02-14

8.  Proton pump inhibitor use and the antifracture efficacy of alendronate.

Authors:  Bo Abrahamsen; Pia Eiken; Richard Eastell
Journal:  Arch Intern Med       Date:  2011-02-14

9.  International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding.

Authors:  Alan N Barkun; Marc Bardou; Ernst J Kuipers; Joseph Sung; Richard H Hunt; Myriam Martel; Paul Sinclair
Journal:  Ann Intern Med       Date:  2010-01-19       Impact factor: 25.391

10.  Evaluation of use of proton pump inhibitors in Greece.

Authors:  George Ntaios; Anastasia Chatzinikolaou; Georgia Kaiafa; Christos Savopoulos; Apostolos Hatzitolios; Dimitrios Karamitsos
Journal:  Eur J Intern Med       Date:  2008-06-16       Impact factor: 4.487

  10 in total
  1 in total

1.  [Facing a dilemma in elderly complex and vulnerable patients: to stop or not to stop prevention?]

Authors:  Laura Llobet Vila; Josep Maria Manresa Domínguez; José Manuel Carmona Segado; Alícia Franzi Sisó; Rosa Vallès Balasch; Isabel Martínez Díaz
Journal:  Aten Primaria       Date:  2017-12-06       Impact factor: 1.137

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.